Citation

Meyer G, Gitahy Falcao Faria C, Beck M, Riutort M, Michel B, Javelot H. Int. Clin. Psychopharmacol. 2022; 37(5): 225-228.

Copyright

(Copyright © 2022, Lippincott Williams and Wilkins)

DOI

10.1097/YIC.0000000000000408

PMID

35695655

Abstract

Switching antipsychotic medication must be done carefully to ensure patient safety and a successful response. Here, we present two major psychotic decompensations that occurred following a switch to aripiprazole in two patients with schizophrenia. Mr. X was treated with paliperidone and experienced residual anxiety. Thus, a switch to aripiprazole was planned with risperidone and a gradual decrease in paliperidone. Initially, an increase in aripiprazole resulted in remission of his residual symptoms. However, two weeks later, he presented an anxiety relapse with persecutory ideas which required hospitalization. Mr. Y, who was treated for many years with risperidone, presented with a treatment resistant psychotic episode. A switch to aripiprazole enhanced his clinical condition. Despite the initial improvement, soon after discharge from the hospital, the patient presented psychotic symptoms requiring home intervention. Ultimately, the patient in the midst of a delusional recrudescence, had killed himself when the health care team arrived. A strong dopamine antagonist may lead to the development of dopaminergic upregulation. The addition of a partial agonist to these hypersensitive neurotransmitter pathways could explain these episodes. We agree with previous reports and recommend careful management when switching from strong dopamine antagonists to aripiprazole.

Language: en

Keywords

Humans; Male; *Suicide; *Antipsychotic Agents/adverse effects; Aripiprazole/adverse effects; Paliperidone Palmitate; Risperidone/adverse effects